Search

Your search keyword '"Stein, Mark A."' showing total 3,084 results

Search Constraints

Start Over You searched for: Author "Stein, Mark A." Remove constraint Author: "Stein, Mark A."
3,084 results on '"Stein, Mark A."'

Search Results

56. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.

57. Longitudinal Stability of Neural Correlates of Pediatric Attention Deficit Hyperactivity Disorder: A Pilot Study of Event Related Potentials and Electroencephalography.

60. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

68. Introduction

69. Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study

71. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

72. At long last Leo

76. Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

77. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer

80. Cognitive aspects of childhood asthma

82. List of Contributors

83. A closer look at common practice valuation approaches: Asset-based approach.

84. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

85. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

87. A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850

88. Supplementary Table from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth

89. Supplementary Figure from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth

90. Data from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth

91. PD24-06 ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL

92. Supplementary Figure 3 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

93. S3. Methods for ellagic acid, urolithin A, quercetin, and resveratrol pharmacokinetics from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

95. S4. Supplementary Results: Prior ADT Treatment from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

96. Supplementary Figure S4.1 from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

97. Data from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

98. Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer

99. Supplementary Figures 1-6, Supplementary Tables 1-5 from First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

100. Supplementary Figure 1 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Catalog

Books, media, physical & digital resources